アラバマ州における非小細胞肺癌の臨床試験
アラバマ州内の拠点で、非小細胞肺癌に関する36件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Southern Cancer Center, P.C., Daphne
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07365319177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Central Alabama Research ( Site 0108), Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07190248A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Southern Cancer Center Pc, Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Southern Cancer Center Pc, Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Alabama Oncology, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alabama Oncology, Shelby, Alabaster
- Alabama Oncology, Bessemer, Bessemer
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- 他9件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Clearview Cancer Institute (Crestwood), Huntsville
- Clearview Cancer Institute, Huntsville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07489066A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Southern Cancer Center, PC, Daphne
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
- Infirmary Cancer Care, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0487, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- UAB Medicine - UAB Hospital, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07488676A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0347, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The University of Alabama, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06914128A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Central Alabama Research, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/25更新 · NCT06216301DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳〜89歳 · 全性別 · 2026/06/15更新 · NCT06364917Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572MYLUNG Consortium Part 3: Observational Study
- Southern Cancer Center, PC, Daphne
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/18更新 · NCT05885698Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/08更新 · NCT05363280Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
- Thomas Hospital, Fairhope
- Mobile Infirmary Medical Center, Mobile
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
被験者募集中
18歳以上 · 全性別 · 2026/04/30更新 · NCT05297734Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
- The University of Alabama at Birmingham Hospital, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/24更新 · NCT06841055GEMINI-NSCLC: NSCLC Biomarker Study
- Alabama Oncology, Birmingham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/02/05更新 · NCT05236114SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- XCancer Research Network/Dothan Hematology & Oncology, Dothan
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/24更新 · NCT06228326ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。